LCTX — Lineage Cell Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.91m
- $201.01m
- $14.56m
Brief: Lineage Cell Therapeutics Inc Files For Mixed Shelf Of Upto $75 Million - SEC Filing
Brief: Lineage Cell Therapeutics Posts Q4 Earnings Per Share $0.01
Brief: Lineage Cell Therapeutics Raises $35.9 Million From Sales Of Marketable Securities Holdings And An At-The-Market Equity Offering
Brief: Lineage Cell Therapeutics Says On May 1, Filed A Sales Agreement Prospectus With SEC In Connection With Offer And Sale Of $25 Mln Of ATM Shares
Brief: Lineage Enters Into Exclusive Agreement With Neurgain Technologies To Evaluate Novel Delivery System For OPC1 To Treat Spinal Cord Injury
Brief: Lineage Cell Therapeutics Announces Change To Executive Team
Brief: Lineage Cell Provides Update On OPC1 Cell Therapy Program For Treatment Of Spinal Cord Injury
Brief: Lineage Cell Therapeutics Presents New Opregen Data For Dry AMD With GA At 2020 American Academy Of Ophthalmology Annual Meeting
Brief: Lineage Cell Therapeutics Completes Patient Enrollment In Phase 1/2A Clinical Study Of OpRegen Cell Therapy
Brief: Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results And Provides Business Update
Lineage: Surges as cancer vaccine shows promise in early-stage study
Brief: Lineage Cell Therapeutics Inc Says VAC2 Demonstrated Remarkably Potent Induction Of Immune Responses In All Patients Dosed To Date
Brief: Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority For Development Of A Bio-Retinal Patch For Treatment Of Retinal Diseases In Partnership With Precise Bio
Brief: Lineage Cell Therapeutics- Receives $24.6 Mln Payment From Juvenescence
Brief: Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results And Provides Update On All Clinical Programs
Brief: Lineage Cell Therapeutics Announces Extension Of Opregen Development Grant From Israel Innovation Authority
Brief: Lineage Cell Provides Update On OPC1 Cell Therapy Program For Spinal Cord Injury
Brief: Lineage Cell Therapeutics Reinitiates Patient Enrollment In Clinical Study Of Opregen
Brief: Lineage Cell Therapeutics Reports First Quarter Results